We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Basic View | Expanded View
 Showing 1-20 of 86 Articles
Case Report/Case Series 
Justin J. Finch, MD; Jenna Wald, MD; Katalin Ferenczi, MD; Saima Khalid, MD, MPH; Michael Murphy, MD

Importance  Nonsexual acute genital ulceration (NAGU) is a rare vulvar skin condition typically affecting girls and young women, characterized by acute onset of singular or multiple painful vaginal ulcers. The etiology of this ulcerative dermatosis has not been identified, although it has been associated with systemic infections. ...

Invited Commentary 
Harvey Lui, MD, FRCPC
Fifteen years ago the US Food and Drug Administration approved the use of photodynamic therapy (PDT) in dermatology for the treatment of actinic keratosis (AK). Photodynamic therapy using topical agents in combination with visible light has been investigated extensively with a general consensus that in cutaneous oncology, PDT is probably ...
Research Letter 
Dana Saadeh, MD; Mazen Kurban, MD; Abdul-Ghani Kibbi, MD; Ossama Abbas, MD
Plasmacytoid dendritic cells (PDCs) are specialized dendritic cells with a significant role in antiviral resistance.1,2 Plasmacytoid dendritic cells have never been studied in orf infection.
JAMA Dermatology Clinicopathological Challenge 
Eric Duerr, BS; Jennifer Villaseñor-Park, MD, PhD; Lisa Grandinetti, MD
Topics: dermatology
Original Investigation 
Gayatri Patel, MD, MPH; April W. Armstrong, MD, MPH; Daniel B. Eisen, MD
Includes: Supplemental Content

Importance  Photodynamic therapy (PDT) is used extensively to treat actinic keratoses (AKs). An analysis of the effectiveness of PDT compared with other treatments may help physicians decide what role it should play in their own clinical practices.

Objective  To determine the effectiveness of PDT for the ...

Original Investigation 
Nancy E. Thomas, MD, PhD; Anne Kricker, PhD; Weston T. Waxweiler, MD; Patrick M. Dillon, MD; Klaus J. Busam, MD; Lynn From, MD; Pamela A. Groben, MD; Bruce K. Armstrong, MBBS, DPhil; Hoda Anton-Culver, PhD; Stephen B. Gruber, MD, MPH, PhD; Loraine D. Marrett, PhD; Richard P. Gallagher, MA; Roberto Zanetti, MD; Stefano Rosso, MD; Terence Dwyer, MD; Alison Venn, PhD; Peter A. Kanetsky, MPH, PhD; Irene Orlow, PhD; Susan Paine, MPH; David W. Ollila, MD; Anne S. Reiner, MPH; Li Luo, PhD; Honglin Hao; Jill S. Frank, MS; Colin B. Begg, PhD; Marianne Berwick, MPH, PhD; for the Genes, Environment, and Melanoma (GEM) Study Group
Includes: Supplemental Content

Importance  Previous studies have reported that histopathologically amelanotic melanoma is associated with poorer survival than pigmented melanoma; however, small numbers of amelanotic melanomas, selected populations, lack of centralized pathologic review, or no adjustment for stage limit the interpretation or generalization of results from prior studies.

Objective  ...

Case Report/Case Series 
Frank W. Chen, MD; Diane Tseng, MD, PhD; Sunil Reddy, MD; Adil I. Daud, MD; Susan M. Swetter, MD

Importance  Eruptive melanocytic nevi (EMN) are characterized by the sudden onset of numerous melanocytic nevi and have been traditionally described in the setting of immunosuppression. Selective BRAF inhibitors, such as vemurafenib cause multiple cutaneous adverse effects, including the formation of cutaneous squamous cell carcinoma, as well as ...

Samuel J. Balin, MD, PhD; Raymond L. Barnhill, MD, MSc
Reason dictates that rapidly growing melanomas carry a worse prognosis than those that are quiescent. Indeed, much focus has been given to calculating the growth index of melanomas as defined by their mitotic rate1,2—a process that requires counting the number of mitoses in several high-power fields. As expected, mitotic rate ...
Topics: melanoma
We have all experienced the patient with red legs, referred for refractory “cellulitis” not responding to systemic antibiotics. Primary care, urgent care, hospitalist, and emergency department physicians are on the front line seeing these patients; however, they often lack the training that allows them to recognize cellulitis mimickers. This constitutes ...
JAMA Dermatology Clinicopathological Challenge 
Katherine M. Hunt, BS; Rebecca Kissel, MD; Lucia Seminario-Vidal, MD, PhD
Original Investigation  FREE
Sarah Shen, MBBS, BMedSci; Rory Wolfe, BSc, PhD; Catriona A. McLean, FRCPA, MD; Martin Haskett, FACD; John W. Kelly, FACD, MD
Includes: Supplemental Content

Importance  Mitotic rate is now recognized as having independent prognostic significance in melanoma survival. However, its clinicopathologic associations have not been the focus of any previous study.

Objective  To identify a set of patient and tumor characteristics associated with high-mitotic-rate melanoma with the aim of facilitating ...

Original Investigation 
Ryan Y. Arakaki, MD; Lauren Strazzula, BA; Elaine Woo, MD; Daniela Kroshinsky, MD, MPH

Importance  Cellulitis is a common and costly problem, often diagnosed in the outpatient setting. Many cutaneous conditions may clinically mimic cellulitis, but little research has been done to assess the magnitude of the problem.

Objective  To determine if obtaining dermatology consultations in the outpatient primary care ...

Case Report/Case Series 
John T. O’Malley, MD, PhD; Vivette D. D’Agati, MD; William H. Sherman, MD; Marc E. Grossman, MD
Includes: Supplemental Content

Importance  Acquired cutis laxa is a rare cutaneous manifestation of hematologic malignancy. We report a case of γ heavy chain deposition disease (HCDD) associated with acquired cutis laxa, renal involvement, and hypocomplementemia and propose a mechanism of elastic fiber degradation in the skin of this patient with ...

Case Report/Case Series 
Christoph T. Ellebrecht, MD; Eun J. Choi, BS; David M. Allman, PhD; Donald E. Tsai, MD, PhD; William A. Wegener, MD, PhD; David M. Goldenberg, ScD, MD; Aimee S. Payne, MD, PhD
Includes: Supplemental Content

Importance  B-cell depletion with the anti-CD20 antibody rituximab is highly effective for pemphigus vulgaris (PV) treatment. However, most patients experience relapse, and intravenous rituximab infusions are expensive. Therefore, cost-effective anti-CD20 therapies are desirable.

Observations  A compassionate-use investigational new drug protocol was approved to administer veltuzumab, a ...

Davide Altamura, MD; Francesco Simonacci, MD; Torkan Hirbod, MD; Evdokia Arkoumani, MD; Roberto Verdolini, MD, FRCP
Imiquimod is a topical immune response modifier with potent antiviral and antitumor effects. It induces an immune-mediated response, demonstrated by changes in the lymphocytic infiltrate and locally produced cytokines.1,2
JAMA Dermatology Clinicopathological Challenge 
Alicia J. Little, PhD; Antonio Subtil, MD, MBA; Jaehyuk Choi, MD, PhD
Joseph C. Pierson, MD
Shortly after I began prescribing certain topical medications in the early 1990s, I started to question the ritual. That universal thrill new clinicians experience when confidently knowing the diagnosis and its treatment was soon tempered by the realization that many patients had arrived already knowing both, and they resented a ...
H. Ray Jalian, MD; Mathew M. Avram, MD, JD
Since the passing of the Congressional Balanced Budget Act in 1997,1 the scope of practice of mid-level health care providers, namely nurse practitioners and physician assistants (hereinafter “mid-level providers”), has rapidly expanded. While originally envisioned to improve access to primary care in underserved areas under the supervision of a physician, ...
Topics: dermatology
Original Investigation  FREE
Brett Coldiron, MD; Mondhipa Ratnarathorn, MD

Importance  Mid-level providers (nurse practitioners and physician assistants) were originally envisioned to provide primary care services in underserved areas. This study details the current scope of independent procedural billing to Medicare of difficult, invasive, and surgical procedures by medical mid-level providers.

Objective  To understand the scope ...

The Cutting Edge 
Nicholas A. Richmond, MD; Sonia A. Lamel, MD; Liza R. Braun, MD; Alejandra C. Vivas, MD; Thomas Serena, MD; Robert S. Kirsner, MD, PhD
Includes: Supplemental Content

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Subscribe to the journal